Compare AbbVie Inc (ABBV) vs Lumen Technologies Inc (LUMN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Lumen Technologies Inc — how do they compare? AbbVie Inc trades at $253.48 (market cap $449.91B), while Lumen Technologies Inc trades at $6.49 (market cap $6.64B). The key difference: AbbVie Inc is far larger — about 67.8× Lumen Technologies Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Lumen Technologies Inc pays none. Which is the better fit depends on your goals.
| ABBV | LUMN | |
|---|---|---|
Market Cap | $449.91B | $6.64B |
Sector | Health | Media |
52-Week High | $261.07 | $11.83 |
52-Week Low | $184.85 | $3.70 |
Enterprise Value | $513.38B | $18.26B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
LUMN trades at $6.44, up 0.16% on the day, with a bearish technical signal but bullish oscillators. The company reported a net loss of $1.74B in 2025, though it beat EPS estimates in two of the last three quarters. Recent news highlights the completion of the Alkira acquisition, aimed at boosting its AI-era networking capabilities. Revenue has declined from $17.5B in 2022 to $12.4B in 2025, with a negative net income margin of -14.34%.
The outlook remains challenging due to persistent losses and high debt, but strategic acquisitions and a 15% forward free cash flow yield offer potential upside. Risks include execution hurdles in integrating acquisitions and intense telecom competition. Analyst consensus is a Hold with a $8.25 price target, suggesting cautious optimism amid fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →
